A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Janus Kinase 1
Janus Kinase 2
Protein Kinase Inhibitors
Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).